glp-1

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including…

C’è un crescente corpo di prove, che allude al potenziale dei farmaci a base di peptide-1 simile al glucagone (GLP-1) nel trattamento di condizioni diverse dal diabete e dall’obesità, tra…

Studies examining the risks of GLP-1 weight-loss drugs, distinguishing alpha-gal syndrome from other GI disorders, and comparing medications to slow the progression of liver disease in patients with alcohol-use disorder…